top of page

Browse by category

Search

SURMOUNT-5: Tirzepatide shows superior weight loss over semaglutide

SURMOUNT-5: Tirzepatide shows superior weight loss over semaglutide

SURMOUNT-5: Tirzepatide shows superior weight loss over semaglutide

Seventy-two week outcomes from the SURMOUNT-5 clinical trial have shown that tirzepatide (Zepbound) met the primary endpoint and all five...

SURMOUNT-5: Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

SURMOUNT-5: Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

SURMOUNT-5: Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomised clinical trial that found Zepbound...

SURMOUNT-5: Tirzepatide and semaglutide go head-to-head in battle of weight loss drugs

SURMOUNT-5: Tirzepatide and semaglutide go head-to-head in battle of weight loss drugs

SURMOUNT-5: Tirzepatide and semaglutide go head-to-head in battle of weight loss drugs

Eli Lilly and Company has registered its intent to carry out a Phase 3b clinical trial that will see the company’s tirzepatide (Mounjaro)...

Five-year RefluxStop outcomes demonstrate favourable food passageway-related outcomes

9 hours ago

Tirzepatide plus menopause hormone therapy aids weight loss

9 hours ago

Consuming more protein may protect semaglutide patients taking from muscle loss

11 hours ago

Back to Top

bottom of page